Abstract:Chimeric antigen receptors (CAR) are engineered fusion proteins constructed from antigen recognition, signaling, and costimulatory domains that can be expressed in cytotoxic T cells with the purpose of reprograming the T cells to specifically target tumor cells. CAR T-cell therapy uses gene transfer technology to reprogram a patient's own T cells to stably express CARs, thereby combining the specificity of an antibody with the potent cytotoxic and memory functions of a T cell. In early-phase clinical trials, CAR T cells targeting CD19 have resulted in sustained complete responses within a population of otherwise refractory patients with B-cell malignancies and, more specifically, have shown complete response rates of approximately 90% in patients with relapsed or refractory acute lymphoblastic leukemia. Given this clinical efficacy, preclinical development of CAR T-cell therapy for a number of cancer indications has been actively investigated, and the future of the CAR T-cell field is extensive and dynamic. Several approaches to increase the feasibility and safety of CAR T cells are currently being explored, including investigation into the mechanisms regulating the persistence of CAR T cells. In addition, numerous early-phase clinical trials are now investigating CAR T-cell therapy beyond targeting CD19, especially in solid tumors. Trials investigating combinations of CAR T cells with immune checkpoint blockade therapies are now beginning and results are eagerly awaited. This review evaluates several of the ongoing and future directions of CAR T-cell therapy.

Research progress in chimeric antigen receptor modiifed T cells targeted glycoprotein tumor marker

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Research status on immunogenicity of chimeric antigen receptor T cell immunotherapy

[Progress in Clinical Studies of Chimeric Antigen Receptor Engineered T Cells for Treatment of Childhood Cancer].

Paving the Way Towards Universal Chimeric Antigen Receptor Therapy in Cancer Treatment: Current Landscape and Progress

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Special Chimeric Antigen Receptor (CAR) Modifications of T Cells: A Review

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy

Current progress in CAR-T cell therapy for tumor treatment

Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy

Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy

CAR trafficking does matter: prospects of ‘Chimeric antigen receptor designed to prevent ubiquitination and downregulation showed durable antitumor efficacy’

The development of CAR design for tumor CAR-T cell therapy

Chimeric Antigen Receptor (Car)-Modified NK Cells Against Cancer: Opportunities and Challenges

Current progress in chimeric antigen receptor-modified T cells for the treatment of metastatic breast cancer

Update of chimeric antigen receptor T cell in malignant melanoma

Advances in research on factors affecting chimeric antigen receptor T‐cell efficacy

Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility